Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23912711
Moustafa-Kamal M, et al. (2013) BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by ╬▓TrCP1. Cell Death Differ 20, 1393-403 23912711
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S69-p - BIM (human)
Modsite: GPLAPPAsPGPFATR SwissProt Entrez-Gene
Orthologous residues
BIM (human): S69‑p, BIM iso2 (human): , BIM iso3 (human): , BIM (mouse): S65‑p, BIM (rat): S65‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
RO-3306 decrease

S93-p - BIM (human)
Modsite: SsLLSRSssGyFsFD SwissProt Entrez-Gene
Orthologous residues
BIM (human): S93‑p, BIM iso2 (human): , BIM iso3 (human): , BIM (mouse): S89‑p, BIM (rat): S89‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AurA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme
KINASE AurA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, modification site within consensus motif
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
okadaic_acid nocodazole augment treatment-induced increase
RO-3306 decrease
C2-ceramide decrease
siRNA increase siRNA for PP2CA increases phosphorylation
BI-D1870 no change compared to control
MLN8054 decrease
siRNA decrease siRNA for AurA decreases phosphorylation
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation

S94-p - BIM (human)
Modsite: sLLSRSssGyFsFDT SwissProt Entrez-Gene
Orthologous residues
BIM (human): S94‑p, BIM iso2 (human): , BIM iso3 (human): , BIM (mouse): S90‑p, BIM (rat): S90‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AurA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme
KINASE AurA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, modification site within consensus motif
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
okadaic_acid nocodazole augment treatment-induced increase
RO-3306 decrease
C2-ceramide decrease
siRNA increase siRNA for PP2CA increases phosphorylation
BI-D1870 no change compared to control
MLN8054 decrease
siRNA decrease siRNA for AurA decreases phosphorylation
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation

S98-p - BIM (human)
Modsite: RSssGyFsFDTDRsP SwissProt Entrez-Gene
Orthologous residues
BIM (human): S98‑p, BIM iso2 (human): , BIM iso3 (human): , BIM (mouse): S94‑p, BIM (rat): S94‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AurA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AurA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, modification site within consensus motif
PHOSPHATASE PPP2CA (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
okadaic_acid nocodazole augment treatment-induced increase
RO-3306 decrease
C2-ceramide decrease
siRNA increase siRNA for PP2CA increases phosphorylation
BI-D1870 no change compared to control
MLN8054 decrease
siRNA decrease siRNA for AurA decreases phosphorylation
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation

S104-p - BIM (human)
Modsite: FsFDTDRsPAPMSCD SwissProt Entrez-Gene
Orthologous residues
BIM (human): S104‑p, BIM iso2 (human): S44‑p, BIM iso3 (human): , BIM (mouse): S100‑p, BIM (rat): S100‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  HEK293T (epithelial)
Cellular systems studied:  cell lines